What the FDA labels say about taking them together
Venetoclax and voriconazole
Voriconazole's FDA label of February 26, 2026 names venetoclax in its drug interactions section; the venetoclax label PlainMeds reads does not name voriconazole. The voriconazole label: “… lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Refer to the venetoclax labeling for safety monitoring and dose reduction in the steady daily dosing phase in CLL/SLL patients. …”
Check it at the source: the venetoclax FDA label on DailyMed (effective May 20, 2026, AbbVie Inc.); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the venetoclax label say about voriconazole?
Venetoclax's label (effective May 20, 2026) does not name voriconazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Venclexta), AbbVie Inc., effective May 20, 2026 (SPL set b118a40d-6b56-cee3-10f6-ded821a97018), via openFDA; the full label on DailyMed
What does the voriconazole label say about venetoclax?
Voriconazole label, drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Venetoclax (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Venetoclax Plasma Exposure Likely to be Significantly Increased; Prevention or Management Recommendations: Concomitant administration of voriconazole is contraindicated at initiation and during the ramp-up phase in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Refer to the venetoclax labeling for safety monitoring and dose reduction in the steady daily dosing phase in CLL/SLL patients. …
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), contraindicationsCoadministration of Voriconazole for injection with venetoclax at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions (7) ].
Source: FDA drug label (Voriconazole, NDA208562), Xellia Pharmaceuticals USA LLC, effective January 11, 2023 (SPL set 9ec6eda2-2f15-423b-9ec6-819379a426e1), via openFDA
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Venetoclax | Voriconazole | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once